Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 482-200-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- repeated dose toxicity: oral, other
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 008
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: Annex V
- GLP compliance:
- yes
- Limit test:
- yes
Test material
- Reference substance name:
- -
- EC Number:
- 482-200-1
- EC Name:
- -
- Cas Number:
- 1184-10-7
- Molecular formula:
- C36H30N3O6P3
- IUPAC Name:
- hexaphenoxy-1,3,5,2λ⁵,4λ⁵,6λ⁵-triazatriphosphinine
- Test material form:
- solid
Constituent 1
Test animals
- Species:
- other: Rat (Sprague-Dawley)
Administration / exposure
- Route of administration:
- oral: unspecified
- Vehicle:
- olive oil
- Details on oral exposure:
- Method of administration:
Gavage - Duration of treatment / exposure:
- Test duration: 28 days
- Frequency of treatment:
- Dosing regime: 7 days/week
- No. of animals per sex per dose:
- Male: 10 animals at 0 mg/kg bw/day
Male: 5 animals at 50 mg/kg bw/day
Male: 5 animals at 250 mg/kg bw/day
Male: 10 animals at 1000 mg/kg bw/day
Female: 10 animals at 0 mg/kg bw/day
Female: 5 animals at 50 mg/kg bw/day
Female: 5 animals at 250 mg/kg bw/day
Female: 10 animals at 1000 mg/kg bw/day
Results and discussion
Results of examinations
- Details on results:
- Clinical observations:
Males: Salivation was noted in the control group.
Salivation and a reddish tear was noted in the 50
mg/kg group.
Salivation, scab formation and exudates on the neck
were noted in the 250 mg/kg group.
Females: Loss of hair was noted in the 250 mg/kg group.
Salivation and loss of hair was noted in the 1000
mg/kg group.
Laboratory findings:
Haematological examinations:
Males: No abnormalities were observed.
Females: Large unstained cells were decreased in the 1000
mg/kg group.
Blood chemical examination:
At termination of dosing period:
Males: Calcium was increased in the 50 and 1000 mg/kg
groups.
Females: No abnormailites were observed.
At termination of recovery period:
Males: Albumin:T-protein-Albumin ratio was increased in the
1000 mg/kg group.
Females: No abnormailites were observed.
Effects in organs:
Organ weights:
At termination of dosing period:
Males: No abnormalities were observed.
Females: Relative brain weight was increased in the 50
mg/kg group.
At termination of recovery period:
Males: No abnormalities were observed.
Females: Absolute heart and spleen weights were decreased
in the 1000 mg/kg group.
Necropsy:
At termination of dosing period:
Males: Whitish region in the heart was observed in the
vehicle group.
Females: Erosion on the skin was observed in the 250 mg/kg
group.
At termination of recovery period:
No abnormalities were observed in either males or females.
Histopathological examiniation:
At termination of dosing periods:
Males: Microgranuloma in the liver, focal myocarditis in
the heart, increased hyaline droplets, solitary cyst
in cortex and medulla in the kidney and aberran
craniopharyngael tissue in the pituitary gland were
noted in the vehicle control group.
Ulcer on skin was noted in the 250 mg/kg group.
Mineralisation in the glangular stomach was noted in
the 1000 mg/kg group.
Females: Mineralisation in corticomedullary junction of the
kidney and cyst formation in pars distalis gland
were noted in the vehicle control group.
Mineralisation in corticomedullary junction of the
kidney was noted in the 1000 mg/kg group.
At termination of recovery period:
No abnormalities were noted in either males or females.
Effect levels
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 1 000 mg/kg bw/day (nominal)
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Classified as: Not classified
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.